Please login to the form below

Not currently logged in
Email:
Password:

Momenta

This page shows the latest Momenta news and features for those working in and with pharma, biotech and healthcare.

Merck confirms sale of biosimilar division

Merck confirms sale of biosimilar division

All told, more than a dozen companies, including Amgen, Samsung Bioepis, Boehringer Ingelheim, Momenta Pharmaceuticals and Sandoz, are developing Humira biosimilars, which may be a factor behind Merck's decision to

Latest news

  • Shire gives up on Momenta-partnered Humira biosimilar Shire gives up on Momenta-partnered Humira biosimilar

    Shire has called time on collaboration with Momenta Pharmaceuticals on the development of a biosimilar version of AbbVie's Humira. ... Momenta said Shire took the decision after a "comprehensive portfolio assessment" that followed its $32bn acquisition

  • Mylan buys into six biosimilars, including Orencia candidate Mylan buys into six biosimilars, including Orencia candidate

    Mylan buys into six biosimilars, including Orencia candidate. Deal with Momenta bolsters biosimilars pipeline for new products. ... Generic pharmaceutical giant Mylan has boosted its position in the emerging biosimilar market via a $245m agreement with

  • Another setback for Teva's laquinimod in MS Another setback for Teva's laquinimod in MS

    but is now facing generic competition in the US from Sandoz/Momenta's Glatopa.

  • Pfizer links with Synthon on generic Copaxone Pfizer links with Synthon on generic Copaxone

    Copaxone (glatiramer acetate) already has one rival in the US market in the form of Sandoz and Momenta's Glatopa, and Pfizer will also try to grab a slice of the

  • Generic Copaxone launches in US Generic Copaxone launches in US

    Generic Copaxone launches in US. Sandoz and Momenta Pharmaceuticals started shipping Glatopa in reaction. ... Immediately, Novartis' Sandoz generics division and partner Momenta Pharmaceuticals started to ship their Glatopa brand of 20mg glatiramer

More from news
Approximately 3 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Building a bright future Building a bright future

    Mylan’s biosimilar of the multiple sclerosis injection therapy copaxane is not gliding to the promised land, and delays have given rivals Momenta and Novartis’Sandoz a tilt at the

  • Deal Watch January 2017 Deal Watch January 2017

    625. Momenta. CSL. Licence. M230 immuno-modulator of Fc receptors. 600. ImmuNext.

  • Deal Watch January 2016 Deal Watch January 2016

    255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept).

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    The LMWH pipeline includes three compounds: certoparin sodium (Embolex; Novartis), semuloparin (Visamerin; Sanofi) and adomiparin (Momenta Pharmaceuticals).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics